Treatment for various kinase-driven cancers have advanced, but there is often a relapse after treatment is discontinued. We have identified a therapeutic cocktail that eliminates this relapse by inhibiting three complementary pathways: c-Fos, Dusp-1 and BCR-ABL tyrosine kinase.
In vivo experiments in an animal model mimicking human CML, AML, and lung cancers showed that treatment with our cocktail fully suppressed the expression of cancer stem cells. A one month drug treatment cured the mice of leukemia and eradicated the cancer stem cells while those treated with only one or two components of the cocktail relapsed, demonstrating that this cocktail provides an effective therapy for leukemia.
For more detailed information regarding this technology, please click here for a non-confidential slide deck.